Summit Securities Group’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$413K Buy
+30,170
New +$411K 0.04% 211
2026
Q1
– Sell
-9,100
Closed -$65.2K – 1288
2025
Q4
$65.2K Hold
9,100
– – 0.01% 554
2025
Q3
$97.2K Hold
9,100
– – 0.02% 400
2025
Q2
$88.1K Hold
9,100
– – 0.02% 388
2025
Q1
$135K Sell
9,100
-19,000
-68% -$292K 0.02% 207
2024
Q4
$419K Buy
28,100
+7,300
+35% +$119K 0.09% 147
2024
Q3
$398K Sell
20,800
-1,000
-5% -$20.7K 0.11% 112
2024
Q2
$451K Buy
+21,800
New +$433K 0.09% 106
2023
Q4
– Sell
-2,294
Closed -$40K – 834
2023
Q3
$40K Buy
2,294
+1,961
+589% +$40.9K ﹤0.01% 306
2023
Q2
$7K Sell
333
-167
-33% -$3.63K ﹤0.01% 805
2023
Q1
$12K Sell
500
-966
-66% -$25.9K ﹤0.01% 678
2022
Q4
$41K Sell
1,466
-553
-27% -$14.1K ﹤0.01% 755
2022
Q3
$47K Buy
2,019
+867
+75% +$26.2K ﹤0.01% 626
2022
Q2
$39K Sell
1,152
-482
-29% -$16.9K ﹤0.01% 618
2022
Q1
$57K Buy
+1,634
New +$55.9K 0.01% 586

Other funds holding OGN

Summit Securities Group's OGN Position: Q3 2026 in Review

Summit Securities Group opened a new position in Organon & Co (OGN) in Q3 2026: 30,170 shares worth $413K. The stake represents 0.04% of the portfolio and ranks #211 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in OGN as recently as Q4 2025.

Summit Securities Group first reported a position in OGN in Q1 2022 and has held it in 15 quarters since. The position peaked at $451K in Q2 2024. 607 funds tracked by Wall St. Rank hold OGN as of Q3 2026.

  • Summit Securities Group held 30,170 shares of Organon & Co worth $413K as of Q3 2026.
  • Organon & Co was a new Summit Securities Group position in Q3 2026.
  • Organon & Co made up 0.04% of Summit Securities Group's portfolio in Q3 2026, its #211 holding.
  • Summit Securities Group first reported a position in Organon & Co in Q1 2022 and has held it in 15 quarters since.
  • Summit Securities Group's Organon & Co position peaked at $451K in Q2 2024.
  • 607 funds tracked by Wall St. Rank held Organon & Co as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.